Top Page
Polynovo
(Sydney:PNV)
Polynovo (PNV) vs. iShares MSCI Australia ETF (EWA)
Polynovo Business Overview & Revenue Model
Polynovo Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 115.58M | 103.19M | 65.24M | 41.44M | 29.16M | 22.16M | Gross Profit |
| 72.83M | 97.71M | 19.33M | 16.23M | 7.83M | 5.01M | EBIT |
| 3.39M | 1.16M | -6.19M | -256.66K | -3.15M | -4.14M | EBITDA |
| 9.38M | 5.17M | -2.71M | 961.93K | -3.41M | -3.21M | Net Income Common Stockholders |
| 5.91M | 5.26M | -4.92M | -1.19M | -4.61M | -4.19M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 8.19M | 45.96M | 46.90M | 6.15M | 7.74M | 11.70M | Total Assets |
| 29.59M | 108.72M | 92.62M | 34.97M | 38.34M | 37.86M | Total Debt |
| 2.42M | 15.38M | 16.04M | 10.99M | 10.00M | 10.03M | Net Debt |
| -5.72M | -30.53M | -30.80M | 4.89M | 2.31M | -1.62M | Total Liabilities |
| 5.07M | 36.60M | 27.24M | 17.26M | 15.99M | 14.04M | Stockholders Equity |
| 24.52M | 72.12M | 65.38M | 17.72M | 22.35M | 23.81M |
| Cash Flow | Free Cash Flow | ||||
| -16.35M | 786.00K | -7.46M | -2.55M | -3.82M | -9.27M | Operating Cash Flow |
| -9.44M | 3.68M | -5.93M | -2.06M | -248.74K | -402.56K | Investing Cash Flow |
| -5.48M | -1.49M | -1.53M | 5.86M | -3.57M | -8.87M | Financing Cash Flow |
| -3.97M | -3.17M | 48.06M | -5.39M | -70.37K | 7.03M |
Polynovo Technical Analysis
Polynovo Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $929.18M | 156.40 | 8.30% | ― | 39.19% | 273.91% | |
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% | |
| $82.91M | ― | -15.86% | ― | ― | ― | ||
54 Neutral | AU$179.35M | ― | -4.06% | ― | 15.90% | 8.52% | |
48 Neutral | AU$152.22M | ― | -58.61% | ― | ― | -74.88% | |
44 Neutral | AU$118.92M | ― | -35.20% | ― | 4.68% | -155.42% | |
42 Neutral | AU$139.66M | ― | -52.37% | ― | 471.29% | -4.58% |
Polynovo Corporate Events
Polynovo Limited has announced a significant change in its shareholder structure, with various entities, including State Street Bank and Trust Company and its subsidiaries, becoming substantial holders. This development indicates a shift in the company’s ownership dynamics, potentially impacting its strategic decisions and market positioning. The involvement of major financial institutions as substantial holders could influence Polynovo’s future operations and stakeholder engagements.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo has released a recording of its May 2025 Investor Update Webcast for shareholders and interested parties who missed the live event. This announcement underscores PolyNovo’s commitment to transparency and stakeholder engagement, potentially strengthening its market position and investor relations.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo announced positive results from a ‘first in human’ study using its NovoSorb BTM technology for cell therapies in treating Type 1 diabetes. The study, presented by Professor Toby Coates, demonstrated the survival and function of human pancreatic islets transplanted into a new site within the skin, offering a promising alternative to the current standard of care. This breakthrough suggests significant potential for NovoSorb in the cell therapy market, potentially creating a new business segment for PolyNovo. The company is in discussions to accelerate research and development in this space, which is projected to reach USD $34 billion by 2034.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited has achieved a significant commercial milestone with the Therapeutic Goods Administration (TGA) clearance of its NovoSorb MTX (4 mm and 6 mm) products in Australia. This clearance allows the products to be marketed and sold, providing healthcare professionals with versatile options for managing soft tissue defects. The NovoSorb MTX is designed to support natural wound healing, particularly for highly exudative wounds or those with uneven wound beds, and addresses clinician demand for products without a sealing membrane. This development enhances PolyNovo’s industry positioning by expanding its product offerings and meeting the needs of plastic surgeons and other healthcare providers.
PolyNovo Limited’s presentation at the Macquarie Australia Conference highlights the company’s ongoing commitment to innovation in wound care technology. While the presentation includes forward-looking statements subject to change, it underscores the company’s strategic focus on expanding its market presence and enhancing its product offerings, which could have significant implications for its stakeholders.
PolyNovo Limited announced an upcoming investor update webcast scheduled for May 16, where it will discuss its financial performance, future outlook, cash and capital adequacy, and growth strategies, including market expansion into China and Japan and the launch of NovoSorb MTX. This update is significant for stakeholders as it highlights PolyNovo’s strategic initiatives to enhance its market position and expand its product offerings, potentially impacting its operations and industry standing.
JPMorgan Chase & Co. and its affiliates have reduced their voting power in Polynovo Limited from 9.06% to 7.98%, as detailed in a recent notice of change of interests. This adjustment in voting power may influence the company’s shareholder dynamics and could have implications for its governance and decision-making processes.
Polynovo Limited, a company in the medical device industry, has seen a change in the substantial holding of its shares by JPMorgan Chase & Co. and its affiliates. The voting power of JPMorgan has increased from 7.53% to 9.06% as of April 14, 2025, indicating a significant shift in shareholder interest and potential influence over company decisions.
PolyNovo Limited has announced the resignation of Mr. Lior Harel from his role as General Counsel and Company Secretary, effective April 15, 2025, as he pursues other opportunities. The responsibilities will be temporarily taken over by CFO Jan-Marcel Gielen until a replacement is appointed, indicating a seamless transition in leadership roles within the company.
Polynovo Limited has experienced a change in the interests of its substantial holder, JPMorgan Chase & Co. and its affiliates, who have increased their voting power from 6.30% to 7.53%. This change reflects a significant shift in the company’s shareholder structure, potentially impacting its market positioning and stakeholder relations.
Polynovo Limited has announced that State Street Corporation and its subsidiaries have ceased to be substantial holders in the company as of April 9, 2025. This change in substantial holding could impact Polynovo’s shareholder structure and influence its market position, as State Street’s exit might affect investor perceptions and future investment strategies.
PolyNovo Limited announced record-breaking unaudited sales and revenue figures for March 2025, with monthly sales reaching A$11.9 million and total revenue hitting A$12.4 million. The company experienced significant growth across multiple regions, particularly in the United States and the United Kingdom, driven by increased account acquisition and the expanded use of their NovoSorb products. The strong financial performance and cash reserves position PolyNovo well to continue its strategic initiatives, including the completion of a new manufacturing facility and R&D innovation center.
Polynovo Limited has announced a significant change in its shareholder structure, with State Street Bank and Trust Company and its associates becoming substantial holders. This development indicates a strategic shift in the company’s ownership, potentially impacting its future governance and market strategies.
Polynovo Limited has experienced a change in the interests of its substantial holder, FIL Limited, which has increased its voting power from 8.63% to 9.65% as of April 3, 2025. This increase in voting power reflects FIL Limited’s ongoing investment in Polynovo, potentially impacting the company’s market positioning and indicating a vote of confidence from a significant shareholder.
PolyNovo Limited has achieved significant regulatory milestones for its NovoSorb MTX product line, receiving FDA 510k clearance in the U.S. for up to 6 mm thickness with new indications for tunneled/undermined wounds. This clearance is expected to enhance the product’s versatility in managing deep soft tissue defects and expand its use in plastic and reconstructive surgery. Additionally, NovoSorb MTX with a 2 mm thickness has been approved for marketing in Australia and for importation in India, broadening its market presence. These developments are poised to strengthen PolyNovo’s position in the medical technology industry and provide new opportunities for growth, particularly benefiting plastic surgeons and healthcare professionals.
Polynovo Limited has experienced a change in the interests of a substantial holder, FIL Limited, which has increased its voting power from 6.48% to 7.56%. This change reflects FIL Limited’s active trading in Polynovo’s common stock, with several buy and sell transactions occurring between February 20, 2025, and March 5, 2025. The increase in voting power suggests a strengthened position for FIL Limited within Polynovo, potentially impacting the company’s shareholder dynamics and strategic decisions.
PolyNovo Limited has announced a change in leadership with the departure of CEO Mr. Swami Raote, effective June 10, 2025. Dr. Robyn Elliott, a non-executive director with extensive experience in business development and operational strategy, will serve as Acting CEO until a permanent replacement is found. This leadership change is aimed at continuing the company’s growth and transformation, with an executive search for a new CEO underway. The Board is also reviewing its structure and composition to ensure effective governance and succession planning.